Drugs / GRC 54276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05878691 | Jun 2022 → Jul 2027 expected | lymphoma | Glenmark Specialty S.A. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-03-16 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas glenmarkpharma.com ↗
Now that the FDA has accepted our IND application, we look forward to initiating the ongoing Phase 1/2 study at the US sites. |
| 2022-04-11 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma glenmarkpharma.com ↗
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-16 | Glenmark Pharmaceuticals Ltd. India | Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas glenmarkpharma.com ↗ |
| 2022-04-11 | Glenmark Pharmaceuticals Ltd. India | Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin’s Lymphoma glenmarkpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRC 54276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05878691 ↗ |
| Action | Inhibit | “HPK1 Inhibitor GRC 54276” NCT05878691 ↗ |
| Route | Oral | “GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.” NCT05878691 ↗ |
| Target | HPK1 | “HPK1 Inhibitor GRC 54276” NCT05878691 ↗ |